Zambon entered in an exclusive license agreement to register and commercialize riluzole Oral Film in Europe for ALS

Warren, NJ, November 13, 2019 – Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that it granted a license to Zambon S.p.A. for the development and commercialization of Riluzole Oral Film (ROF) in the European Union for the treatment of amyotrophic lateral sclerosis (ALS). Zambon is a multinational pharmaceutical company strongly committed to innovating cure and care to make patients’ lives better, with a focus on the central nervous system (CNS) therapeutic area. “We are proud to announce that Zambon will register and commercialize in the European Union Riluzole Oral Film. Thanks to this collaboration with Aquestive, Zambon will further strengthen its commitment to orphan diseases and to the CNS area, enriching its portfolio with a new formulation that will concretely help patients. Zambon is committed to improve people’s quality of life through innovative medicines and modern therapeutic solutions where they are mostly needed,” said Roberto Tascione, CEO of Zambon S.p.A. Download FOLLOW ZAMBON LinkedIn Instagram Main navigation Group Who we are Our Purpose Mission & Values History Zambon places How we work Pharma Leadership & Organization Model Ethics and Compliance Value report Innovation Global Medical Office R&D Zach System Zcube Production Pharma Plants CDMO Virtual Plant Zach System People&Culture Working in Zambon Life at Zambon Development in Zambon News&Media Contacts Contact us Medical Information Pharmacovigilance ZAMBON COMPANY S.P.A. ©2024, ALL RIGHTS RESERVED SWITCHBOARD: +39 02665241 Footer Accessibility Statement Company info Contact Us Cookie Policy Legal Notice Privacy Policy SUPPLIER QUALIFICATION Whistleblowing Disclosure Associations and Institution Funding Pharmacovigilance

The release as fetched from its publisher. zambon.com ↗